Later-Line Therapies Used in Unresectable or Metastic Melanoma

Considering Immunotherapy Rechallenge and TILs for Recurrent Mucosal Melanoma

During a live event, Sapna Patel, MD, and participants discussed second-line treatment selection for a patient with mucosal melanoma and considered how the limited available data shape that choice.

When Consensus Outpaces Capacity in Second-Line Melanoma

During a live event, Sapna Patel, MD, discussed how to sequence second-line therapy for a patient with BRAF-mutant melanoma after immunotherapy and targeted therapy.

Streamlining the TIL Therapy Pipeline for Melanoma

Ravi Amaravadi, MD, discusses how his team approaches tumor-infiltrating lymphocyte therapy to avoid delays that could keep patients from getting treated.

Late-Line Use of TILs in Melanoma Leaves Few Bridging Options

During a live event, participants discuss barriers to access and bridging strategies for tumor-infiltrating lymphocytes in melanoma.

Considering Lifileucel Use in Patients With Brain-Metastatic Melanoma

During a live event, Daniel Olson, MD, reviewed a patient case of recurrent melanoma with brain metastases and addressed treatment options.

Exploring TIL Sequencing in Melanoma Based on European Experience

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

Walking Through the TIL Therapy Process in Advanced Melanoma

During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating lymphocytes in patients with melanoma.

Considering Lifileucel for PD-1–Refractory Advanced Melanoma

During a live event, Michael C. Lowe, MD, MA, discussed how lifileucel provides an option for patients with unresectable or metastatic melanoma.

Lifileucel Offers Promising Long-Term Efficacy in Advanced Melanoma

During a live event, Barbara T. Ma, MD, MS, examined trial data on lifileucel tumor infiltrating lymphocyte therapy in patients with advanced melanoma.

Awareness of TIL Therapy for Melanoma Is Crucial for Timely Referral

During a live event, Barbara T. Ma, MD, MS, reviewed guidelines on management and best practices for the use of tumor-infiltrating lymphocytes in melanoma.

Behind the C-144-01 Study of Lifileucel in Melanoma

Theresa Medina, MD, discusses treatment with lifileucel in patients with advanced melanoma and the background of the C-144-01 study.